IHL 0.00% 4.1¢ incannex healthcare limited

@JohnK123What do you mean 'Looks like something may have been...

  1. 162 Posts.
    lightbulb Created with Sketch. 410
    @JohnK123

    What do you mean 'Looks like something may have been leaked...'?

    @thevinnys did inform us all - as he always does really well - when the Form 20-F registration statement was filed on 31 January, it would take 2 or so weeks to list on the NASDAQ.

    Seems like punters getting positioned for what's to come...

    Plus, the company itself announced in the quarterly, "The trial data is being analysed by Novotech, the contract research organization (‘CRO’) engaged by Incannex to manage the study and resulting data. Delivery of the final clinical study report is expected in Q1 2022 and is anticipated to coincide with IHL’s listing on the Nasdaq exchange in the United States."

    Lots of news to come following the US listing:
    - OSA (sleep apnoea) phase 2a results
    - TBI results and update on next steps forward (developed in collaboration with the US National Football League (NFL) which is big!)
    - Pre-IND/IND meeting updates for a suite of development drugs, heading into phase 2b trials
    - IHL-675A phase one recruitment/commencement update for Lung Inflammation, RI, IBD
    - Psi-GAD (psychedelics trial one) recruitment/commencement update
    - Potential psychedelics trial two announcement (flagged for several months)
    - Nasdaq compliance listing to kick the news season off
    - Loyalty options issue update

    50 cents seems extremely cheap and trading in the 40 cent range was absurd for this long.

    Management are positioning the company to become the next global leader in psychedelics/ CBD drug development.

    Yes, the above news is set to drive capital into the share price in the next few weeks/months. But what's way more exciting is the potential to have multiple drugs in the phase 2b stage later this year/early next year, with multi-billion dollar market potential, and no competition. It's worth asking the question: What's a pending global leader worth with multiple drug candidates in the phase 2B stage -- and in exciting sectors -- with no competition with billion dollar plus market potential worth?

    The psychedelics arm is got to be worth at a least a billion!

    What's the rest of the business worth?

    Final words: think MULTIPLE phase 2b trials in the psychedelics and CBD sectors coming soon. This is where the real value is set to be created and, if just one of six programs is successful (forget how many we're doing these days...there's so much going on!), we're looking at a multi billion dollar US market cap.

    To your first million,
    -Trading For Millions.
 
watchlist Created with Sketch. Add IHL (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.